Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Reham Elshimy has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long Intergenic Non-Coding RNA 00511 (LINC00511) Genetic Variations and Haplotypes in Breast Cancer: A Case-Controlled Study and Bioinformatics Analysis

    by Shorouk Eldash, Eman F. Sanad, Reham A. A. Elshimy, Ahmad A. Hady, Dina Nada, Nadia M. Hamdy

    Long intergenic non-coding RNA 00511 (LINC00511) has been involved in the development of several types of cancer including breast cancer (BC). Several single nucleotide polymorphisms (SNPs) can be found in the genomic regions of long non-coding RNAs (lncRNAs) and are associated with the tumorigenesis of many cancers. The objective of the current study is to assess whether LINC00511 SNPs (rs11657109, rs9906859, rs17780195, rs1558535, and rs4432291) could be related with BC incidence in the Egyptian population. Five SNPs of LINC00511 were analyzed in a case–control study of 267 BC cases and 150 controls. Logistic regression analysis was used to test the association between LINC00511 SNPs and BC incidence. We found that the TT genotype of rs11657109 significantly increased BC incidence (OR: 2.177, 95%CI: 1.260–3.763) and this SNP was associated with high incidence of luminal A BC specifically using different genetic models. Haplotype (A09 A91 A35 G95 T59) was strongly associated with an increased BC incidence as it was totally absent in controls. These findings suggest that LINC00511 SNP rs11657109 is associated with BC susceptibility in the Egyptian population.


  • Open Access

    Micro RNA-148a Targets Bcl-2 in Patients with Non-Small Cell Lung Cancer

    by Ghada Nabil Elnaggar, Niveen M El-Hifnawi, Abeer Ismail, Maha Yahia, Reham Elshimy

    Objective: Lung cancer is one of the most prevalent cancers and the leading cause of cancer-related deaths worldwide. MicroRNAs regulate more than 60% of human genes, including tumor suppressor genes and oncogenes. Accordingly, they can affect cancer risk. This study aimed to evaluate the role of serum miR-148a as a non-invasive biomarker in non-small cell lung cancer (NSCLC) patients and to assess the correlation between miR-148a and Bcl-2, as one of its target proteins. Materials and Methods: A total of 50 newly diagnosed NSCLC cases and 30 apparently healthy controls were recruited in this study. MiR-148a level was measured by TaqMan- Real time RT-PCR assay and Bcl-2 level was measured by ELISA. Results: Significant lower expression of serum miR-148a and higher serum Bcl-2 levels were observed in NSCLC patients as compared to the control group (p


  • Open Access

    Molecular Profiling of Breast Cancer Susceptibility of Obese or Insulin-Resistant and Pre-Diabetic Patients Using ITLN1 and CD295 SNPs

    by Nadia M. Hamdy, Reham A. El-Shemy

    Mutations in cluster of differentiation (CD) 295 gene, encoding class I cytokine receptor, are associated with obesity and breast cancer (BC). SNPs in the adipocyte-inferred novel cytokine intelectin 1 (ITLN1) remain understudied in connection to CD295 polymorphisms and diabetes mellitus (DM) or a pre-diabetic state, as well as to DNA damage seen in BC. We will explore whether CD295 (ID rs6700896) and ITLN1 (rs rs952804) SNPs impact BC with or without DM, insulin resistance (IR) or obesity. Effects of ITLN1 or CD295 polymorphism(s) on DNA damage in BC were also examined. Blood samples from 170 women with BC (including 33 and 48 with DM and pre-diabetes, respectively) and from 108 age-matched women in the control group were collected. Plasma insulin, leptin, CD295, and ITLN1 levels were measured by ELISA. DNA damage was assessed using an alkaline comet assay. BC cases with clinical stage T II and positive LN as well as tumor histologic grade III, presence of obesity, pre-diabetic events, DM or IR were associated with CD295 rs6700986 mutant homozygous (CC) and heterozygous (CT) genotype and ITLN1 rs952804 mutant heterozygous genotype (CT) (P ≤ 0.05). Tail DNA (%) and tail moment units were significantly associated with CD295 rs6700986 CT and ITLN1 rs952804 TT genotypes. C allele (CT+CC vs. TT) and T allele (TT+CT vs. CC) for CD295 rs6700986 and ITLN1 rs952804, respectively, were associated with BC risk (P ≤ 0.05). ITLN1 (rs952804) and CD295 (rs6700986) SNPs should be considered as BC associated-susceptibility risk factors in obese, insulin resistant, or pre-diabetics. Graphical Remarks/Highlights: ITLN1 and CD295 polymorphism testing might be utilized for accessing BC susceptibility in either obese or insulin resistant, pre-diabetic patients. A modestly increased risk of BC in women harboring the C allele of CD295 rs6700986 polymorphism and the T allele of the ITLN1 rs952804, where: Tumor clinical stage T II and positive LN involvement as well as the tumor histologic grade III, obesity existence, pre-diabetic event and being diabetic as well as IR cases were associated with CD295 rs6700986 mutant homozygous (CC) and heterozygous (CT) genotype and ITLN1 rs952804 mutant heterozygous cases (CT) ( P ≤ 0.05). Tail DNA (%) and tail moment unit were significantly associated with CD295 rs6700986 CT genotype and ITLN1 rs952804 TT. These SNPs could be considered as BC associated risk factor. In dominant effect of the C allele (CT+CC vs TT) and the T allele (TT+CT vs CC) for CD295 rs6700986 and ITLN1 rs952804, respectively, were associated with BC events and risk ( P ≤ 0.05). CD295 rs6700986 and ITLN1 rs952804 SNPs may be considered BC-associated risk for G3, T2, +LN, obesity, pre-diabetic/diabetic and IR in BC patients.

  • Expression of Plasma miRNA-221 in Colorectal Carcinoma Patients and its Diagnostic Significance in Comparison with p53 Expression

    by Omar Youssef, Amal Fawzy, Reham Elshimy, Alhadi Almangush, Ahmed Mahmoud, Iman Loay

    Background: Colorectal carcinoma development progresses through a sequence of normal mucosa-polyp-carcinoma. Early detection of premalignancy is crucial for improved outcomes. We evaluated the diagnostic performance of plasma miRNA-221 and its feasibility in discriminating premalignant from malignant neoplasms and correlating it with immunohistochemical p53 expression. Methods: A total of 109 plasma samples were collected (76 carcinoma, 14 premalignant, and 19 controls). MiRNA-221 was quantified by qPCR for calculation of Delta Ct using RNU6B as endogenous control. p53 immunohistochemical staining was performed on corresponding tissue. Results: Plasma miRNA-221 and p53 in tissues were significantly overexpressed in the malignant group when compared with the premalignant and control groups. Plasma miRNA-221 was increased in late-stage tumors with nodal or distant metastasis. ROC curve construction for distinguishing between malignant and premalignant tumors revealed a cutoff value of 2.97 with 74% sensitivity, 79% specificity, 73.7% positive predictive value and 78.6% negative predictive value (AUC = 0.824; p = 0.001). Plasma miRNA-221 significantly correlated with p53 in cancer samples (r = 0.507). Conclusions: MiRNA-221 could have a diagnostic role in differentiating malignant from premalignant neoplasms and could also serve as a predictive marker indicating tumor progression.